Two kynurenine hydroxylase inhibitors, (m nitrobenzoyl)-alanine (mNBA) and 3,4-dimethoxy-[ -N-4-(nitrophenyl)thiazol-2yl]-benzenesulfonamide (Ro 61-8048), have been tested as neuroprotective agents on brain lesions induced by bilateral carotid occlusion in gerbils or by middle cerebral artery occlusion in rats, The percentage of lesioned pyramidal neurones fo und in the hippocampal CAl region of gerbils subjected to bilateral carotid occlusion for 5 minutes decreased fr om 92 ± 10% in vehicle-treated animals to 7 ± 6% after mNBA (400 mg/kg intraperitoneally, three times at 1, 30, and 180 minutes after occlusion) or to 10 ± · 11 % after Ro 61-8048 (40 mg/kg intraperitoneally, three times). A significant reduction in infarct volumes also was found when the kynuren ine hydroxylase inhibitors were given to rats after permanent N-methyl-D-aspartate (NMDA) receptor antagonists have been proposed as therapeutic tools in numerous neurologic and psychiatric disorders such as epilepsy, stroke, neurodegenerative diseases, opiate addiction, and anxiety disorders (Meldrum, 1985) . It has been shown, however, that their administration may cause neuronal toxicity (Olney et aI., 1989) and a long series of other side effects, so that the benefit-to-risk ratio frequently is not acceptable for clinical studies (Small and Buchan, 1997) . One of the possible approaches to locally reduce Abbreviations used: KYNA, kynurenic acid; MCAO, middle cere bral artery occlusion; mNBA, (m-nitrobenzoyl)-alanine; NMDA, N methyl-D-aspartate; Ro 61-8048, 3,4-dimethoxy-[ -N-4-(nitrophenyl) thiazol-2yl]-benzenesulfonamide.
middle cerebral artery occlusion (from 207 ± III mm 3 in ve hicle-treated rats to 82 ± 18 and to 62 ± 57 mm 3 in rats treated with mNBA, 400 mg/kg intraperitoneally, or with Ro 61-8048, 40 mg/kg intraperitoneally, respectively). The administration of mNBA (400 mg/kg intraperitoneally) or Ro 61-8048 (40 mg/kg intraperitoneally) to gerbils with a dialysis probe in their dorsal hippocampus or to rats with a dialysis probe in their parietal cortex significantly increased kynurenic acid concentration in the dialysates. The data suggest that inhibition of kynurenine hydroxylase could be a new avenue to reduce neuronal loss in brain ischemia. Key Words: Brain ischemia-Kynurenine Kynurenic acid-(m-Nitrobenzoyl)-alanine-N-methyl-D aspartate-Quinolinic acid.
NMDA receptor function is the use of kynurenine hy droxylase inhibitors (Moroni et aI., 1991) . These agents increase kynurenine availability for kynurenic acid (KYNA) synthesis and may decrease the formation of quinolinic acid. Kynurenic acid, a tryptophan metabolite present in low concentrations in the nervous tissue (Mo roni et aI., 1988) , is a glycineb receptor antagonist (Stone, 1993) , and at larger concentrations, it also interacts as an antagonist with glutamate recognition sites of NMDA and a-amino-3-hydroxy-5-methyl-4-isoxazolepropionate receptors; quinolinic acid, on the contrary, is an NMDA receptor agonist with excitotoxic properties (Schwarcz et aI., 1983) .
Kynurenic acid and its derivatives have been shown to reduce neuronal damage in primary neuronal cultures exposed to excitotoxins (Moroni et aI., 1992) , to reduce the infarct volume after middle cerebral artery occlusion (MCAO) in rats (Chen et aI., 1993) , and to protect hip pocampal pyramidal neurones after transient carotid oc clusion in gerbils (Pellegrini-Giampietro et aI., 1994) .
However, KYNA crosses the blood-brain barrier with difficulty, and thus large doses are necessary to signifi cantly increase its concentration in the brain. To obtain a sufficient increase in brain KYNA content, experiments have been performed with suitable KYNA precursors (kynurenine or indolpyruvic acid) or with probenecid, an inhibitor of the transport mechanism, which is respon sible for its elimination from the brain (Moroni et aI., 1988; Nozaki and Beal, 1992) . A large increase in brain KYNA content also has been shown after the adminis tration of inhibitors of kynurenine hydroxylase, a major kynurenine metabolizing enzyme, and this increase has been associated with functional effects, including neuro protection after ischemic challenge or after excitotoxin injections (Moroni et aI., 1991; Speciale et aI., 1996a; Miranda et aI., 1997) . New potent and selective inhibi tors of this enzyme recently have been described (Roever et aI., 1997) , and we have studied their effects on the neuronal damage found in models of focal or global brain ischemia in rodents. We also evaluated the time course and the extent of kynurenine hydroxylase inhibi tor-induced changes in KYNA concentrations in the ex tracellular spaces of brain areas, which are known to be affected by ischemic challenges, to evaluate the mecha nism of the neuroprotective effects of these enzyme in hibitors.
MATERIALS AND METHODS
All the experiments were formally approved by an ethical committee and were performed according to the rules of the University of Florence (Florence, Italy). Male Sprague-Dawley rats (body weight 220 to 280 g) and Mongolian gerbils (body weight 60 to 80 g) (purchased from Morini, Reggio Emilia, Italy) were used.
Global forebrain ischemia in gerbils
Gerbils were anesthetized with a mixture of 2% halothane, 75% nitrogen, and 20% oxygen. A ventral midline neck inci sion was performed to isolate both common carotid arteries, which were occluded with microarterial clips for 5 minutes. At the end of the occlusion period, the clips were released, allow ing restoration of carotid blood flow, and the incision was sutured. Halothane administration was discontinued immedi ately after carotid occlusion, and the animals that remained unresponsive for approximately 20 minutes were considered exposed to forebrain ischemia. Body temperature was moni tored and maintained at 37 ± 0.5°C with a rectal thermistor and a heating pad until the animals had fully recovered from the anesthesia. The animals then were placed in a warm environ ment (30°C), and their rectal temperature was periodically re corded for 3 hours. Gerbils were selected for these experiments because they lack interconnection between the carotid and the vertebrobasilar circulation, so that a complete global forebrain ischemia may be induced by occlusion of the common carotid arteries at the neck (Kirino, 1982) . The extent of hippocampal damage found after bilateral artery occlusion was evaluated 7 days after surgery. The animals were killed by decapitation, and the brains were rapidly removed and placed in dry ice. Coronal sections (20 fLm) were cut in a cryostat and stained with toluidine blue. The microscopic sections for each animal were analyzed by counting the number of CAl pyramidal neu-J Cereb Blood Flow Metab. Vol. 19, No. 7, 1999 rones and hilar cells that appeared to be histologically normal (Kirino, 1982; Pellegrini-Giampietro et a!., 1994) .
Middle cerebral artery occlusion in rats
Anesthesia was induced with 5% halothane in air and main tained with the lowest acceptable concentration of the anes thetic (in most animals, 2%). The left middle cerebral artery was occluded at the proximal portion according to Tamura and coworkers (1981) . With the animal placed in the lateral posi tion, a skin and muscle incision between the left eye and the left external ear was made, and the temporalis muscle was re tracted. A small burr hole was opened in the basal surface of the temporal bone between the orbita and the foramen ovale. The middle cerebral artery was occluded with a bipolar electroco agulator in the segment starting near its origin and ending where the artery crosses the inferior cerebral vein; after occlu sion, the artery was severed. Body temperature was measured with a rectal probe and kept at 37°C with a negative feedback system (Harvard Homeotermic Blanket Control Unit, Harvard Apparatus, South Natick, MA, U.S.A.) for the duration of the surgical procedure. The animals then were placed in a warm environment for at least 6 hours. Blood pressure and blood gas were not measured, since wounds were sutured quickly (the whole procedure required approximately 15 minutes), and the animal recovered from anesthesia shortly thereafter. Twenty four hours after the lesion, animals were decapitated, and the brains were frozen in dry ice. Coronal sections 20-fLm thick then were prepared in a cryostat and stained with toluidine blue. Lesion area and infarct volume were determined using a com puter-assisted image analysis system (Image-Pro Plus, 3.0, Sil ver Spring, MD, U.S.A.). A small group of animals again was anesthetized 24 hours after MCAO, each chest was opened, and 10 mL of a solution containing 2% 2,3,5-triphenyltetrazolieum chloride (Sigma, Milan, Italy) in saline was slowly injected into the left cardiac ventricle. Twenty minutes later, brains were removed and placed in 4% buffered formalin. Within 2 days, 2-mm thick coronal slices were prepared, and the infarct areas were measured using the computer-assisted image analysis sys tem mentioned earlier.
Administration of mNBA or Ro 61-8048 3,4-Di methoxy -[-N-4-( nitropheny l)thiazol-2y l]-benzene sulfonamide (Ro 61-8048) was solubilized in dimethyl sulfox ide and injected in small volumes intraperitoneally. The maxi mal amount of dimethyl sulfoxide injected was 100 fLL, and controls received an equal amount of solvent. (m-Nitroben zoyl)-alanine (mNBA) was directly solubilized in Ringer solu tion. In the dialysis experiments, the compounds were injected once in rats and twice in gerbils.
Implantation of the dialysis membrane
The animals were anesthetized with chloral hydrate (300 mg/kg intraperitoneally) and placed in a stereotaxic apparatus. The skull was opened, and a transverse microdialysis probe (AN 69 membrane, Dasco, Italy; 220-fLm internal diameter; 31O-fLm external diameter, molecular weight cutoff above 15000 d), prepared according to Ungerstedt (1984) , was in serted into the rat parietal cortex or the gerbil dorsal hippocam pus and fixed with a screw and dental cement as previously reported (Carpenedo et aI., 1994) . The microdialysis tubing was covered with epoxy glue along its entire length, except for the region corresponding to the cortex or dorsal hippocampus. Di alysis fibers were implanted through small burr holes drilled into the skull and kept in place with screws and dental cement. The coordinates (for fiber inlet and outlet) for the rats were -0.2 mm from the bregma (A-P) and -2.2 mm from the skull surface (H), and for the gerbils, -1.8 (A-P) and -2.4 (H). The length of the exposed membrane surface was 4 mm (for both rats and gerbi Is).
Ringer solution (in mmol/L: NaCI 122, KCI 3. 1, CaCI2 2.3) flowed through the probe at a rate of 3.5 fLUmin for 40 min utes. The animals then were placed in individual cages after closing the probe openings. Fifteen hours later, the animals were again connected to the perfusion apparatus. At least I hour of stabilization was allowed before collecting the perfus ate for KYNA determination.
The recovery of KYNA into the dialysis fluid, measured with the probes used for both rats and gerbils, was 10.5 ± 2%. Data were not corrected for probe recovery.
Measurements of KYNA in the dialysates
The KYNA was measured using HPLC with post-column derivatization and fluorimetric detection (Carpenedo et aI., 1994) . The dialysate was directly injected into the HPLC ap paratus. A reverse-phase column (5 10 OD52 5pherisorb l5teroglass, Perugia, Italy]) was used, and separation was ob tained using 50 mmollL sodium acetate buffer (pH 6.20) and 8% acetonitrile at a now rate of 1.0 mUmin as a mobile phase. The post-column derivatizing agent was zinc acetate (0.5 moll L) at a flow rate of 0.6 mUmin. Fluorimetric detection was obtained using a fluorimeter (Perkin Elmer model LC 240) with an excitation wavelength of 344 nm and an emission of 398 nm.
Statistical analysis
Data were compared using analysis of variance followed by Tukey-Kramer multiple comparison test to determine differ ences between the various treatment groups. Values were ex pressed as mean ± 5D.
RESULTS
Effects of mNBA and Ro 61-8048 on ischemia-induced neuronal damage in the gerbil
CAl region of the dorsal hippocampus
Saline-treated gerbils subjected to bilateral carotid oc clusion for 5 minutes went into a postischemic coma.
None of the animal displayed behavioral seizures or other signs of neurologic impairment. Spontaneous mo tility was recovered approximately 30 minutes after isch emia. Seven days later, histologic examination of the dorsal hippocampus showed that most (92 ± 10%) pyra midal cells in the CA I region were damaged (Fig. 1) .
The mean number of intact pyramids counted in a section of the CA l region of the dorsal hippocampus decreased from 290 ± 40 (n = 10, mean ± SD) in nonischemic controls to 23 ± 16 in saline-treated gerbils (n = 18).
Giving mNBA (400 mg/kg intraperitoneally) or Ro 61-8048 (40 mg/kg intraperitoneally), administered three times to gerbils at I, 30, and 360 minutes after reperfu sion, induced a dramatic attenuation of postischemic cell loss. Similarly, the mean number of intact hilar cells counted in each section of the dorsal hippocampus de creased from 56 ± 8 (n = 10, mean ± SD) to 24 ± 6 (n = 10, mean ± SD) after the ischemic challenge. Animals treated with the doses mentioned earlier of either mNBA or Ro 61-8048 and exposed to ischemia had in each section of their hilus 45 ± 9 and 42 ± 7 intact cells, respectively (n = 12 animals per group, mean ± SD),
suggesting that the hilar cells also were protected by treatment with large doses of the kynurenine hydroxylase inhibitors.
Intraperitoneal administration of lower doses of the compounds (200 or 20 mg/kg, respectively) given three times according to the schedule reported earlier did not reduce ischemic damage (Fig. 1) . Similarly, when the compounds were injected twice (1 and 30 minutes after reperfusion) at 400 and 40 mg/kg, respectively, pyrami dal cell loss was no different than that in the controls. (Table 1) . Neuroprotection was present after administration of the larger doses and was particularly evident in the cortical area of heavily affected sections.
Damage also was reduced in the subcortical regions.
Effects of mNBA and Ro 61-8048 on extracellular brain kynurenic acid concentrations
It has been previously reported that mNBA adminis tration to rats with a dialysis probe in their hippocampus significantly increases KYNA concentrations in the di alysates (Carpenedo et aI., 1994) . In the current experi ments, we found that mNBA significantly increased Similar experiments performed in rats with a dialysis probe in their cortex showed that mNBA (400 mg/kg intraperitoneally) increased KYNA concentrations in the dialysis perfusates from 16.5 ± 0.9 to 85 ± 9.6 nmollL, and Ro 61-8048 (40 mg/kg intraperitoneally) increased it from 15 ± 0.9 to 45 ± 14 nmollL. The time course of this increase is reported in Fig. 2B . 
DISCUSSION
Kynurenine hydroxylase inhibitors have been reported to increase brain kynurenine and KYNA content (Moroni et aI., 1991; Speciale et aI., 1996b) , to reduce spontane ous locomotor activity, and to increase the threshold of electroshock or audiogenic-induced seizures in rats and mice (Carpenedo et aI., 1994) . Interestingly, qualitatively similar pharmacologic effects have been described after systemic administration of large doses of glycine recep tor antagonists (Sing et aI., 1990) , and it has therefore been proposed that these enzyme inhibitors reduce NMDA receptor function in vivo (Moroni et aI., 1991) .
Activation of NMDA receptors plays a key role in the neuronal damage found in models of global ischemia in gerbils and focal ischemia in rats (Chen et aI., 1993; Pellegrini-Giampietro et aI., 1994) . The experiments re ported here show that inhibition of kynurenine hydrox ylase results in strong neuroprotection after ischemic in sult and are therefore in line with the hypothesis that by shifting kynurenine metabolism toward KYNA forma tion, it is possible to reduce glutamate receptor activation and ischemic neuronal damage. Figure 2 shows, how ever, that KYNA concentrations in the extracellular spaces of the gerbil hippocampus increase from 2.3 ± 1.2 to 56 ± 15 and from 2.2 ± 0.8 to 48 ± 10 nmollL after administration of neuroprotective doses of mNBA or Ro 61-8048, respectively. Similarly, in the rat cortex, neu roprotective doses of mNBA or Ro 61-8048 increase KYNA concentration in the dialysates from 16.5 ± 0.9 to 85 ± 9.6 and from 15 ± 0.9 to 45 ± 14 nmol/L, respec tively. Considering that probe recovery is approximately 10% and that the affinity of KYNA for the glycine rec ognition site of the NMDA receptors is 10 to 30 /LmollL (Pellegrini-Giampietro et aI., 1989) , it can be concluded that the concentrations of KYNA required to reduce the function of ionotropic glutamate receptors should be ap proximately one order of magnitude larger than those found in brain dialysates. However, it is reasonable to assume that in the vicinity of the synaptic cleft the con centrations of KYNA are significantly larger than those measured in the dialysis fluid. This possibility is sup ported by immunocytochemical observations showing that the enzyme kynurenine aminotransferase, which is responsible for KYNA synthesis, is located mostly in glial cells in close apposition to the excitatory synapses (Du et aI., 1992) . It also should be considered that the Km of kynurenine for rat brain kynurenine amino transferase is in the millimolar range, thus suggesting that precursor availability is the major limiting factor for KYNA for mation. Since kynurenine production depends on in dol amine 2,3-dioxygenase activity and since ischemia strongly induces this enzyme (Saito et aI., 1993) , it is possible that KYNA formation in animals exposed to brain ischemia and treated with kynurenine hydroxylase inhibitors is larger than that found in the microdialysis experiments reported in Fig. 2 . This also could be im portant in gerbils because kynurenine hydroxylase in hibitors were administered twice in microdialysis experi ments, whereas neuroprotection was obtained only when a third administration was given.
The second mechanism possibly involved in the strong degree of neuroprotection of suitable doses of either mNBA or RO 618418 derives from the observation that KYNA synthesis in the brain, but not in the kidney, is significantly reduced by the lack of glucose, lactate, or pyruvate or by modifications of the ionic environment (Hodgkins and Schwarcz, 1998 rently are in progress to study this possibility.
Also notice that the direct product of kynurenine hy droxylase activity is 3-0H-kynurenine, a metabolite pro vided with excitotoxic action in neuronal cell lines (East man and Guilarte, 1989) and able to cause, in a concen tration-dependent manner, either necrotic or apoptotic types of neuronal death (Okuda et aI., 1998) . Structure activity studies show that 3-0H-kynurenine, and other o-aminophenols, may be subject to oxidative reactions initiated by their conversion to quinoneimines, a process associated with concomitant production of oxygen derived free radicals (Hiraku et aI., 1995) . The involve ment of these reactive species in the pathogenesis of ischemic neuronal death has been widely studied in the last several years, and it has been shown that oxygen derived free radicals and glutamate-mediated neurotrans mission cooperate in the development of ischemic neu ronal death (Pellegrini-Giampietro et aI., 1990) . In par ticular, kynurenate derivatives provided with the ability to scavenge for free radicals are particularly potent in reducing excitotoxic damage in vitro (Moroni et aI., 1992) and ischemic damage in vivo (Pellegrini Giampietro et aI., 1994) . It is therefore reasonable to propose that the reduction in 3-0H-kynurenine synthesis and the associated decrease in the production of oxygen derived free radicals contribute to the strong neuropro tective action exerted by mNBA or Ro 61-8048.
Finally, kynurenine hydroxylation is one of the steps required for the synthesis of quinolinic acid, a compound provided with excitotoxic properties. Either mNBA or Ro 61-8048 is able to reduce blood and brain quinolinic acid content in immune-activated rodents (A. Chiarugi, 1998, unpublished data) , and this could contribute to their pharmacologic effects in brain ischemia.
Apart from the relative role that each of the earlier mentioned neurochemical effects of kynurenine hydrox ylase inhibitors play in neuroprotection, the current ex periments show that the brain damage found after focal or global ischemia may be reduced by appropriate ad ministration of mNBA or Ro 61-8048 and that adminis tration of these agents is effective when performed after the ischemic challenge. A single administration of either mNBA or Ro 61-8048 was sufficient to significantly reduce brain damage in MCAO rats, and at least three administrations (the last performed 6 hours after occlu sion of the carotids) were necessary to reduce the death of pyramidal neurones in gerbils.
The kynurenine pathway of tryptophan metabolism has been widely studied in relation to inflammatory, de generative, or excitotoxic insults. A local accumulation of KYNA associated with a reduction in NMDA receptor function has been obtained by administering indolpyru vate (Russi et aI., 1989) , kynurenine (Nozaki and Beal, 1992) , or enzyme inhibitors (Carpenedo et aI., 1994; Speciale et aI., 1996b) . In particular, it has been shown that large doses of kynurenine reduce NMDA toxicity in newborn rats (Nozaki and Beal, 1992) and that pretreat ment with kynurenine hydroxylase inhibitors may reduce ischemic damage in the gerbil hippocampus (Speciale et aI., 1996b) . Our results further support the concept that kynurenine hydroxylase is an interesting target to indi rectly modulate NMDA receptor function in vivo and
show that the inhibition of this enzyme is sufficient to reduce neuronal loss in widely accepted models of brain ischemia.
